Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Clinical trial NCT05245071 · TERMINATED

Trial details

NCT number: NCT05245071
Sponsor: Sanofi
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-squamous Non-small Cell Lung Cancer

Start date: 2022-06-01
Primary completion: 2024-03-06
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.